Maximum quantity allowed is 999
Please select the quantity
CAS RN: 117570-53-3 | Product Number: D5235
Vadimezan
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- DMXAA
- 2-(5,6-Dimethyl-9-oxoxanthen-4-yl)acetic Acid
- ASA-404
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days |
|---|---|---|---|
| 50MG |
$129.00
|
10 | Contact Us |
| 250MG |
$413.00
|
4 | 17 |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | D5235 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__7H__1__4O__4 = 282.30 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 250MG-Glass Bottle with Plastic Insert (View image), 50MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 117570-53-3 |
| Reaxys Registry Number | 4262852 |
| PubChem Substance ID | 468591309 |
| MDL Number | MFCD00870555 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
Properties (reference)
| Melting Point | 264 °C |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
| RTECS# | ZD5536200 |
Transport Information:
| H.S.code* | 2932.99-000 |
Application
DMXAA: A Compound Used as a Tumor Vascular Disputing Agent and an Immune Adjuvant
DMXAA (other names: vadimezan, ASA404) is a tumor vascular disputing agent (VDA) that can cause a specific and irreversible destruction of established tumor vessels. Reportedly, DMXAA induces apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core. DMXAA showed anti-tumor effects against solid tumors in mouse models but subsequently failed in human clinical trials in 2010.
DMXAA is also a potent type-I interferon (IFN) inducer, and can be used as an adjuvant that targets a specific innate immune signaling pathway. (The product is for research purpose only.)
DMXAA is also a potent type-I interferon (IFN) inducer, and can be used as an adjuvant that targets a specific innate immune signaling pathway. (The product is for research purpose only.)
References
- An overview on Vadimezan (DMXAA): The vascular disrupting agent (a review)
- The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant
- Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.